Elicio Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdatesGlobeNewsWire • Wednesday
Elicio Therapeutics to Present New Preliminary Data from the Ongoing AMPLIFY-7P Phase 1/2 Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual MeetingGlobeNewsWire • 04/25/24
Elicio Therapeutics to Present Updated Clinical T Cell and Antigen Spreading Response Data from the Ongoing AMPLIFY-201 Phase 1 Study of ELI-002 and Preclinical Data on ELI-007 and ELI-008 at the AACR Annual MeetingGlobeNewsWire • 04/05/24
Elicio Therapeutics Reports 2023 Financial Results and Provides Corporate UpdatesGlobeNewsWire • 03/29/24
Elicio Therapeutics Announces Upcoming Presentations at the American Association for Cancer Research (AACR) Annual MeetingGlobeNewsWire • 03/06/24
Elicio Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceGlobeNewsWire • 02/05/24
Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating TCR-T Cell Therapy in Combination with Lymph Node-Targeted Amphiphile-Immunotherapy Enhanced Anti-Tumor Function and Eradicated Solid TumorsGlobeNewsWire • 01/25/24
Elicio Therapeutics to Present ELI-002 7P (AMPLIFY-7P) Trial in Progress Poster on Phase 1/2 Study of Lymph Node-Targeted Vaccine at ASCO GI SymposiumGlobeNewsWire • 01/17/24
Elicio Therapeutics to Present at the B. Riley Securities 4th Annual Oncology ConferenceGlobeNewsWire • 01/16/24
Elicio Therapeutics Announces First Patient Dosed in Randomized Phase 2 Pancreatic Cancer StudyGlobeNewsWire • 01/11/24
Nature Medicine Publishes Updated Preliminary Phase 1 Data From Elicio Therapeutic's AMPLIFY-201 Phase 1 Solid Tumor Study of ELI-002GlobeNewsWire • 01/09/24
Elicio Therapeutics to Present at the H.C. Wainwright 4th Annual Precision Oncology Virtual ConferenceGlobeNewsWire • 12/04/23
Elicio Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate UpdatesGlobeNewsWire • 11/09/23
Elicio Therapeutics Presents Updated Preliminary Immunogenicity Data from the Ongoing Phase 1 Study of ELI-002 and New Preclinical Data on ELI-007 and ELI-008 at the Society for Immunotherapy of Cancer (SITC 2023) Annual MeetingGlobeNewsWire • 11/03/23
Elicio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer's (SITC 2023) Annual MeetingGlobeNewsWire • 10/11/23
Elicio Therapeutics Presents Updated Preliminary Data Including Promising Relapse-Free Survival Data from the Phase 1 Study of ELI-002 at AACR Special Conference: Pancreatic CancerGlobeNewsWire • 09/27/23
Elicio Therapeutics Receives $2.6 Million Grant from the Gastro-Intestinal (GI) Research Foundation to Fund Research for Two Therapeutic Cancer VaccinesGlobeNewsWire • 09/07/23
Elicio Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceGlobeNewsWire • 09/06/23
Elicio Therapeutics to Present Phase 1 Data on Cancer Vaccine Candidate, ELI-002, in Patients with High Relapse Risk Pancreatic and Colorectal Cancers at the AACR Special Conference on Pancreatic CancerGlobeNewsWire • 09/05/23
Elicio Therapeutics Announces Appointment of Megan Filoon as General Counsel and Dr. Thian Kheoh as Senior Vice President of BiometricsGlobeNewsWire • 08/28/23